On July 15, Bristol-Myers Squibb declined 3.19% in regular trading, trading at $57.32/share, with turnover of $403 million. The stock fell alongside a broadly weak pharmaceutical sector.

The decline came amid heightened investor concerns about biopharma pricing power heading into Q2 earnings season. Bank of America recently highlighted loss-of-exclusivity headwinds as a key risk for companies like Bristol-Myers Squibb, lowering its price target to $66 from $67. The analysts noted that companies facing patent cliffs continue to underperform peers with cleaner growth outlooks.

Within the Pharmacy sector, the overall performance was weak. Among individual stocks, Eli Lilly fell 2.3%, Johnson & Johnson fell 1.7%, Merck fell 2.84%, Pfizer fell 1.08%, and AstraZeneca fell 2.68%. The company is scheduled to report Q2 earnings on July 30, with consensus EPS expectations of $1.61.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)